Bal Pharma Consolidated September 2022 Net Sales at Rs 75.31 crore, up 12.11% Y-o-Y
NULL15-11-2022
BAL PHARMA LTD. - 524824 - Unaudited Financial Results For The Quarter And Half Year Ended 30.09.2022.
Board of Directors of the Company has met today and inter alia transacted the following business. 1.Taken on record and approved the Unaudited financial results of the Company for the quarter and half year ended 30.09.2022. A copy of the standalone and consolidated financial results together with the balance sheets, cash flow statements and limited review reports issued by the statutory auditors of the Company with un modified opinion is enclosed . 2.Convened Extra Ordinary meeting of the shareholders of the Company on 14th December 2022 to take their approval for filing application with NCLT for the merger of Golden Drugs Pvt Ltd, a wholly owned subsidiary of the Company. 3.Approved the allotment of 1,17,500 equity shares to the employees of the Company who has exercised the stock options vested on them, under Bal Pharma Ltd employee stock option plan 2014. The Board meeting commenced at 5.30 p.m and concluded at 6.20 p.m on 14.11.2022.14-11-2022
BAL PHARMA LTD. - 524824 - Board Meeting Outcome for Outcome Of The Board Meeting-Unaudited Financial Results For The Quarter And Half Year Ended 30.09.2022.
Board of Directors of the Company has met today and inter alia transacted the following business. 1.Taken on record and approved the Unaudited financial results of the Company for the quarter and half year ended 30.09.2022. A copy of the standalone and consolidated financial results together with the balance sheets, cash flow statements and limited review reports issued by the statutory auditors of the Company with un modified opinion is enclosed . 2.Convened Extra Ordinary meeting of the shareholders of the Company on 14th December 2022 to take their approval for filing application with NCLT for the merger of Golden Drugs Pvt Ltd, a wholly owned subsidiary of the Company. 3.Approved the allotment of 1,17,500 equity shares to the employees of the Company who has exercised the stock options vested on them, under Bal Pharma Ltd employee stock option plan 2014. The Board meeting commenced at 5.30 p.m and concluded at 6.20 p.m on 14.11.2022.14-11-2022
BAL PHARMA LTD. - 524824 - Board Meeting Intimation for Un-Audited Standalone And Consolidated Financial Results For The Quarter & Half Year Ended 30.09.2022.
BAL PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/11/2022 ,inter alia, to consider and approve 1.Un-audited standalone and consolidated financial results for the quarter & half year ended 30.09.2022. 2.To allot equity shares to the eligible employees, upon exercise of ESOP''s. 3. To convene Extra Ordinary General Meeting ( EGM ) for merger of Golden Drugs Pvt Ltd , a wholly owned subsidiary of the Company.04-11-2022
BAL PHARMA LTD. - 524824 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
We are submitting to the exchange intimation received from our R&T agents i.e TSR Darashaw Ltd, Mumbai, regarding loss of share certificates by one of our shareholder.21-10-2022
BAL PHARMA LTD. - 524824 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Based on the certificate's received from our R&T agents i.e TSR Darashaw Pvt Ltd, we would like to confirm that the details of securities dematerialized / rematerialized during the quarter ended on 30.09.2022 have been furnished to all the stock exchanges where the equity shares of the Company are listed, within the prescribed time limit. The Share certificates received for dematerialization, if any has been mutilated and cancelled after due verification and the name of the depository has been substituted in the records as registered owner, within 15 days of the receipt of the certificate of security.03-10-2022
BAL PHARMA LTD. - 524824 - Closure of Trading Window
Pursuant to the Code of conduct of the Company and as per the amended provisions of SEBI (Prohibition of Insider Trading) Regulations, 2015, we wish to inform the exchange that the trading window for dealing with the securities of the Company on the designated employees and their relatives will be closed from 1st October 2022 and up to 48 hours of the declaration of the unaudited financial results of the Company, for the quarter ended 30/09/2022. The date of the Board meeting for declaration of the unaudited financial results, will be intimated to the exchange in due course.03-10-2022
BAL PHARMA LTD. - 524824 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation regarding loss of share certificate.28-09-2022
BAL PHARMA LTD. - 524824 - Announcement under Regulation 30 (LODR)-Amendments to Memorandum & Articles of Association
We would like to inform the exchanges that the shareholders of the Company at their meeting held on 19.09.2022 has approved the adoption of new set of Memorandum of Association & Articles of Association of the Company, as per the provisions of the Companies Act,2013, through a special resolution. We are submitting to the exchange copy of the revised MOA&AOA of the Company, for your records.23-09-2022
BAL PHARMA LTD. - 524824 - Announcement under Regulation 30 (LODR)-Investor Presentation
Audio Visual recording of the webinar can we assessed through the following weblink https://www.balpharma.com/ip23-09-2022